Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695919 | 0.90 | TP53 (0.51) | NPSR1TP53ALDH1A1KMT2AGAA | |
| SCHEMBL3708992 | 0.90 | TP53 (0.51) | NPSR1TP53ALDH1A1KMT2AGAA | |
| SCHEMBL3706524 | 0.88 | TP53 (0.49) | NPSR1TP53ALDH1A1KMT2AGAA | |
| SCHEMBL538328 | 0.87 | MAPT (0.54) | TP53ALDH1A1KMT2AGAAMAPT | |
| SCHEMBL12099796 | 0.86 | NPSR1 (0.56) | NPSR1TP53ALDH1A1KMT2AGAA | |
| SCHEMBL2677954 | 0.86 | NPSR1 (0.56) | NPSR1TP53ALDH1A1KMT2AGAA | |
| SCHEMBL3702377 | 0.86 | NPSR1 (0.59) | NPSR1TP53ALDH1A1KMT2AGAA | |
| SCHEMBL3698011 | 0.86 | MAPT (0.49) | NPSR1TP53KMT2AGAAMAPT | |
| SCHEMBL2837904 | 0.86 | THRB (0.47) | NPSR1TP53ALDH1A1KMT2AGAA | |
| SCHEMBL3696933 | 0.86 | TP53 (0.47) | NPSR1TP53KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-8173680-B2 | Cannabinoid receptor modulators | 7TM PHARMA A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| US-8173680-B2 | Cannabinoid receptor modulators | 7TM PHARMA A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| US-20100292273-A1 | Cannabinoid Receptor Modulators | 7TM PHARMA A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292273-A1 | Cannabinoid Receptor Modulators | 7TM PHARMA A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| EP-2190822-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-2120931-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CANNABINOID RECEPTOR | 7TM Pharma A/S (DK) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008074982-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CANNABINOID RECEPTOR | 7TM PHARMA A/S (DK) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292273-A1 | Cannabinoid Receptor Modulators | CNR1, CNR2, CBR1 | NPSR1 63/4885TP53 4655/4885ALDH1A1 1244/4885 |
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NPSR1 2001/4885TP53 4668/4885ALDH1A1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.